

1 **Autoantibodies in COVID-19 correlate with anti-viral** 2 **humoral responses and distinct immune signatures**

3

4 **Short title:** COVID-19: Autoantibodies correlate with humoral response

5

6 Patrick Taeschler^{1†}, Carlo Cervia^{1†}, Yves Zurbuchen¹, Sara Hasler¹, Christian Pou², Ziyang
7 Tan², Sarah Adamo¹, Miro E. Raeber¹, Esther Bächli³, Alain Rudiger⁴, Melina Stüssi-
8 Helbling⁵, Lars C. Huber⁵, Petter Brodin^{2,6,7}, Jakob Nilsson¹, Elsbeth Probst-Müller¹, and Onur
9 Boyman^{1,8} *

10

11 ¹ Department of Immunology, University Hospital Zurich, Zurich, Switzerland

12 ² Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet,
13 Solna, Sweden

14 ³ Clinic for Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland

15 ⁴ Department of Medicine, Limmattal Hospital, Schlieren, Switzerland

16 ⁵ Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland

17 ⁶ Pediatric Rheumatology, Karolinska University Hospital, Solna, Sweden

18 ⁷ Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

19 ⁸ Faculty of Medicine, University of Zurich, Zurich, Switzerland

20 [†] Contributed equally

21

22 * Corresponding author: Onur Boyman, MD, Department of Immunology, University Hospital
23 Zurich, Schmelzbergstrasse 26, 8091 Zurich, Switzerland. E-mail: onur.boyman@uzh.ch;
24 phone: +41 44 255 2069.

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 **Acknowledgements**

28 This work was funded by Swiss National Science Foundation grants 310030-172978 and
29 310030-200669 (to OB), 4078P0-198431 (to OB and JN) and NRP78 Implementation
30 Programme (to CC and OB), Digitalization Initiative of the Zurich Higher Education
31 Institutions Rapid-Action Call #2021.1_RAC_ID_34 (to CC), Swiss Academy of Medical
32 Sciences grants 323530-191220 (to CC), 323530-191230 (to YZ) and 323530-177975 (to SA),
33 Forschungskredit Candoc of University of Zurich FK-20-022 (to SA), Young Talents in
34 Clinical Research Project Grant (YTCR 08/20) by the Swiss Academy of Medical Sciences
35 and Bangerter Foundation (to MER), the Clinical Research Priority Program of University of
36 Zurich for CRPP CYTIMM-Z (to OB), the Pandemic Fund of University of Zurich (to OB),
37 and an Innovation Grant of University Hospital Zurich (to OB). We thank the diagnostic
38 laboratories of the University Hospital Zurich, Alessandra Guaita, Claudia Meloni, Jennifer
39 Jörger, Jana Epprecht and Claudia Bachmann for their support, and the members of the
40 Boyman Laboratory for helpful discussions. The study overview graphic was generated with
41 BioRender.com.

42

43 **Abstract**

44 **Background**

45 Several autoimmune features occur during coronavirus disease 2019 (COVID-19), with
46 possible implications for disease course, immunity, and autoimmune pathology. In this study,
47 we longitudinally screened for clinically relevant systemic autoantibodies to assess their
48 prevalence, temporal trajectory, and association with immunity, comorbidities, and severity of
49 COVID-19.

50 **Methods**

51 We performed highly sensitive indirect immunofluorescence assays to detect anti-nuclear
52 antibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCA), along with serum
53 proteomics and virome-wide serological profiling in a multicentric cohort of 175 COVID-19
54 patients followed-up to one year after infection, eleven vaccinated individuals, and 41
55 unexposed controls.

56 **Results**

57 Compared to healthy controls, similar prevalence and patterns of ANA were present in patients
58 during acute COVID-19 and recovery. However, paired analysis revealed a subgroup of
59 patients with transient presence of certain ANA patterns during acute COVID-19. Furthermore,
60 patients with severe COVID-19 exhibited a high prevalence of ANCA during acute disease.
61 These autoantibodies were quantitatively associated with higher SARS-CoV-2-specific
62 antibody titers in COVID-19 patients and in vaccinated individuals, thus linking autoantibody
63 production to increased antigen-specific humoral responses. Notably, the qualitative breadth of
64 antibodies cross-reactive with other coronaviruses was comparable in ANA-positive and ANA-
65 negative individuals during acute COVID-19. In autoantibody-positive patients,

66 multiparametric characterization demonstrated an inflammatory signature during acute
67 COVID-19 and alterations of the B cell compartment after recovery.

68 **Conclusion**

69 Highly sensitive indirect immunofluorescence assays revealed transient autoantibody
70 production during acute SARS-CoV-2 infection, while the presence of autoantibodies in
71 COVID-19 patients correlated with increased anti-viral humoral immune responses and
72 inflammatory immune signatures.

73

74 Word count: 245

75 Max word count: 250

76

77

78

79 **Keywords:** Autoantibodies, Anti-nuclear antibodies, COVID-19, SARS-CoV-2, VirScan

80

81 **Introduction**

82 Acute coronavirus disease 19 (COVID-19) causes a large clinical spectrum, ranging from a
83 mild condition in the majority of cases to fatal disease in 1-2% of subjects.¹⁻³ Several features
84 of acute COVID-19 resemble clinical manifestations of systemic inflammatory and
85 autoimmune diseases, such as fatigue, myalgia, hyperinflammation, thrombosis, and skin
86 rashes.^{3,4} Furthermore, COVID-19 may trigger the onset of autoimmune pathology, as reported
87 for Guillain-Barré syndrome, anti-phospholipid syndrome, vasculitis, and multisystem
88 inflammatory syndrome in children.⁵⁻⁹ *Vice versa*, autoimmune phenomena have been
89 connected to the pathogenesis of severe COVID-19. Pre-existing autoantibodies targeting the
90 type I interferon pathway have been found in about 10% of COVID-19 cases with critical
91 disease.¹⁰⁻¹²

92 Other acute or chronic viral infections have been associated with autoimmune responses, which
93 have been proposed to arise by molecular mimicry, epitope spreading or bystander activation.¹³
94 Various autoantibodies have been described in association with COVID-19, including anti-
95 nuclear antibodies (ANA),¹⁴⁻²⁰ anti-neutrophil cytoplasmic antibodies (ANCA),^{15,16,21} anti-
96 phospholipid antibodies,^{5,8,14,17,19,22} and antibodies targeting different extracellular
97 antigens.^{11,16} While the presence of different autoantibodies has been associated with severe
98 COVID-19 and worse outcome,^{11,15,17-19} it remains unclear to what extent autoantibodies are
99 triggered by acute infection, even though transient autoreactivity and new development of
100 autoantibodies have been suggested in a subgroup of COVID-19 patients.^{16,20} Furthermore,
101 several aspects of autoantibodies in COVID-19, including their interplay with virus-specific
102 humoral responses and their durability after acute infection, need further elucidation. In this
103 study, we comprehensively characterized autoantibodies by using highly sensitive indirect
104 immunofluorescence (IIF) assays in a multicentric prospective cohort of 227 individuals.

105

106 **Results**

107 **Presence of systemic autoantibodies during acute COVID-19 and recovery**

108 We performed a comprehensive immunological characterization of 175 individuals with
109 confirmed COVID-19 up to one year after infection (**Fig. 1A** and **Table 1, Table S1**), including
110 autoantibody screening by IIF, serum proteomics and serological profiling. 41 individuals with
111 negative history and serology for severe acute respiratory syndrome coronavirus 2 (SARS-
112 CoV-2) infection were included as controls (**Fig. 1A** and **Table 1**). Furthermore, eleven
113 unexposed individuals were sampled before and after vaccination with BNT162b2 (**Table S2**).
114 Using a highly sensitive IIF screening assay, we detected titers of 1:320 and above in 17 of 41
115 (41.4%) healthy individuals thus testing positive for ANA (**Fig. 1B**). This prevalence of ANA
116 positivity was similar to that in COVID-19 patients during acute disease (48.0%, odds ratio
117 (OR) = 1.30, $p = 0.49$) as well as six months (47.4%, OR = 1.27, $p = 0.59$) and one year after
118 recovery (42.3%, OR = 1.04, $p = 1$) (**Fig. 1C–E**). Most of the observed ANA titers were just
119 above the positivity threshold of 1:320. Interestingly, we observed a trend of higher ANA
120 prevalence in individuals with severe COVID-19 compared to mild disease during acute
121 infection (OR 1.85, $p = 0.061$), which was significantly higher at six months after recovery
122 (OR = 3.81, $p = 0.0015$) (**Fig. 1C** and **D**).

123 Similarly, we used an IIF assay to detect ANCA. ANCA prevalence was similar in mild
124 COVID-19 patients during acute disease (3.6%) compared to healthy individuals (2.4%) (**Fig.**
125 **1F** and **G**). Conversely, we observed a significantly higher ANCA prevalence in severe acute
126 COVID-19 patients (19.7%), both compared to healthy subjects ($p = 0.0082$) and mild COVID-
127 19 cases ($p = 0.0096$) (**Fig. 1F** and **G**), which returned to ranges seen in healthy individuals
128 after six months (5.1%, $p = 0.61$) and one year (14.3%, $p = 0.15$) (**Fig. 1H** and **I**).

129 In several patients, nuclear ANA, cytoplasmic ANA, or ANCA were detected concurrently,
130 particularly during acute COVID-19 (**Fig. 1J–M**). Moreover, ANCA showed a tendency to be

131 more frequent in ANA-positive (14.3%) compared to ANA-negative (5.5%) individuals during
132 acute COVID-19 ($p = 0.06$) (**Fig. 1K**).

133

134 **Characteristics of ANA and ANCA patterns in acute COVID-19**

135 To gain a qualitative appreciation, we classified ANA patterns according to the international
136 consensus on ANA patterns anti-cell (AC) nomenclature.²³ ANA patterns were very similar in
137 healthy controls and COVID-19 patients at all three sampling timepoints, and in some
138 participants different patterns were detected concurrently (**Fig. 2A–D, Fig. S1A–D**). The most
139 common nuclear patterns were fine-granular nuclear (AC-4 or AC-4 like) and nucleolar (AC-
140 8, AC-9, and AC-10), whereas the most common cytoplasmic patterns were speckled (AC-19
141 and AC-20) (**Fig. 2E–G**).

142 ANCA patterns observed during acute COVID-19 and follow-up were mostly cytoplasmic
143 (**Fig. 2H**). However, cytoplasmic patterns were atypical and, accordingly, none of the ANCA-
144 positive patients showed positivity for either anti-myeloperoxidase (MPO) or anti-proteinase 3
145 (PR3) antibodies (**Fig. 2I**), suggesting other antigen specificities than commonly found in
146 ANCA-associated vasculitis^{24,25}.

147

148 **Temporal trajectory of autoantibodies in individual COVID-19 patients**

149 To appreciate changes in ANA and ANCA on an individual level, we performed paired analysis
150 of all followed-up COVID-19 patients ($n = 129$). For mild and severe COVID-19 patients
151 combined, we observed similar proportions of patients with isolated ANA positivity during
152 acute disease (14.7%) and follow-up (12.4%). However, a trend toward a higher proportion of
153 new ANA development at follow-up visit was evident in patients with severe COVID-19
154 (20.5%) compared to patients with mild COVID-19 (8.2%) ($OR = 2.84$, $p = 0.054$) (**Fig. 3A**
155 **and B**). To also account for subtle changes of IIF patterns, we conducted a blinded, paired

156 analysis of IIF images to identify patterns that were transiently present either during acute
157 disease or follow-up. Strikingly, we found transient patterns in 11 of 62 (17.7%) ANA-positive
158 COVID-19 patients during acute disease, with speckled cytoplasmic (AC-19 and 20), nucleolar
159 (AC-8, 9, 10) and mitotic being the most frequent patterns (**Fig. 3C and D**). In stark contrast,
160 only three of 59 (5.1%) ANA-positive individuals presented with a pattern during follow-up
161 that was not present during acute disease, thus demonstrating that transient ANA patterns were
162 significantly more prevalent during acute COVID-19 ($p = 0.045$) (**Fig. 3C**).

163 For ANCA, we observed that of ten patients that tested positive during acute COVID-19, eight
164 were negative during follow-up, whereas only two remained positive. Furthermore, only one
165 patient newly exhibited positive ANCA at follow-up (**Fig. 3E and F**). Collectively, we found
166 that a subgroup of individuals shows ANA and atypical ANCA production during the acute
167 phase of COVID-19, which usually subsides during follow-up.

168

169 **Virus-specific responses in autoantibody-positive and SARS-CoV-2-vaccinated subjects**

170 To elucidate the influence of autoantibody production during acute infection, we investigated
171 the correlation of autoantibodies with specific humoral immune responses to SARS-CoV-2.
172 We longitudinally assessed SARS-CoV-2 spike 1 (S1)-specific immunoglobulin A (IgA) and
173 IgG titers and found that presence of ANA was associated with higher concentrations of S1-
174 specific antibodies in COVID-19 patients during acute disease, which extended to six months
175 after recovery (**Fig. 4A**). Conversely, one year after recovery, we did not observe any
176 differences (**Fig. S2**). The presence of ANA correlated significantly with S1-specific IgG levels
177 even after accounting for age, disease severity, and sampling timepoint in a multiple linear
178 regression model, which was not the case of S1-specific IgA (**Fig. 4B, Table S3**). Similarly,
179 we found higher S1-specific IgA and a trend toward higher IgG titers in patients that tested
180 positive for ANCA during acute disease (**Fig. 4C**).

181 To elucidate whether autoantibodies were associated with an increased humoral immune
182 response only after natural SARS-CoV-2 infection or also after other antigen-specific immune
183 responses, we measured ANA and S1-specific antibodies in 11 individuals before and after
184 COVID-19 vaccination with BNT162b2 (**Fig. 4D–F, Table S2**). Although a tendency of an
185 increased ANA prevalence following the first vaccine shot was apparent, no significant
186 difference was observed between sampling timepoints (**Fig. 4D**). We observed higher S1-
187 specific IgA in ANA-positive individuals when combining data from two and four weeks after
188 the first vaccine shot, whereas no difference was observed for IgG (**Fig. 4E and F**). In summary,
189 these findings suggest the presence of autoantibodies is associated with increased S1-specific
190 humoral responses following acute COVID-19 up to six months after recovery and following
191 SARS-CoV-2 vaccination.

192

193 **Human virome-wide serological profiling in acute COVID-19**

194 Next, we sought to investigate qualitative aspects of antibody responses during acute COVID-
195 19 with respect to previous anti-viral humoral responses in ANA-positive and ANA-negative
196 individuals. Based on the phage immunoprecipitation sequencing (PhIP-seq) technology
197 (VirScan),²⁶ we performed human virome-wide serological profiling in 97 acute COVID-19
198 patients and 18 healthy controls. We assessed the results of antibodies directed to 112 different
199 viruses (**Table S4**), with data for a total of 87,890 epitopes, consisting of 56-amino acid (AA)-
200 long, overlapping peptides. The library comprised all six human coronaviruses (HCoV)
201 described before the COVID-19 pandemic, including HCoV-HKU1, HCoV-NL63, HCoV-
202 229E, betacoronavirus 1 (BCoV1, including HCoV-OC43), severe acute respiratory syndrome-
203 related coronavirus (SARS-CoV), and Middle east respiratory syndrome-related coronavirus
204 (MERS-CoV).

205 A multivariate analysis using the summed epitope hits per viral species revealed distinct
206 differences in COVID-19 patients compared to healthy controls, which were particularly
207 pronounced more than one week after symptom onset (**Fig. 5A**). Between-group comparisons
208 of COVID-19 patients and healthy controls revealed a significant difference ($p < 0.005$) of
209 summed epitope hits for eight viral species (**Fig. 5B**). Of these, four enterovirus species were
210 more abundant in healthy controls. Conversely, antibodies targeting cytomegalovirus (CMV)
211 and Pegivirus A, and those directed to SARS-CoV and MERS-CoV were significantly more
212 abundant in COVID-19 patients, whereas antibodies targeting the four common coronaviruses
213 HCoV-HKU1, HCoV-NL63, HCoV-229E, and BCoV1, showed a parallel, but insignificant
214 trend ($p > 0.005$) (**Fig. 5B**). Antibodies directed to all coronavirus species correlated positively
215 with time from symptom onset (**Fig. 5C**), thus indicating production of cross-reactive
216 antibodies during acute COVID-19.

217 To further study antibodies targeting CoVs in acute COVID-19, we evaluated serological
218 profiles on a singular epitope level. We found a significantly higher ($p < 0.05$) proportion of
219 COVID-19 patients tested positive for a total of 18 CoV epitopes compared to healthy controls,
220 of which 16 were in the spike and two in the nucleoprotein (**Fig. 5D, Fig. S3A**). Since healthy
221 individuals tested negative for these but positive for only one epitope (**Fig. 5D and E**), we
222 hypothesized these 18 CoV epitopes enriched in COVID-19 patients were targeted by
223 antibodies newly produced during acute COVID-19 and cross-reactive with shared epitopes of
224 other CoVs. Pairwise protein alignment of these epitopes with corresponding SARS-CoV-2
225 proteins allowed identification of regions of SARS-CoV-2 spike and nucleoprotein targeted by
226 cross-reactive antibodies, comprising two segments (AA positions 777–886 and 1105–1195)
227 of spike S2 domain and one segment of nucleoprotein (AA 140–252), which have been
228 previously identified in COVID-19 patients²⁷. Patients with severe COVID-19 tested positive
229 for significantly more cross-reactive antibodies than mild disease patients (**Fig. 5E**). However,

230 no significant difference was observed in ANA-positive compared to ANA-negative patients
231 (**Fig. 5F**), although the proportion of ANA-positive patients that tested positive was slightly
232 higher for most cross-reactive epitopes (**Fig. 5G**).

233 To explore potential correlations of ANA with humoral responses against other viruses, we
234 compared seroreactivity against all tested viral epitopes and ANA positivity. Several epitopes
235 were detected more frequently ($p < 0.005$) in ANA-positive, but not in ANA-negative,
236 individuals (**Fig. 5H**). Three of the identified peptides were located on Epstein-Barr virus
237 (EBV) nuclear antigen 2 (EBNA-2), to which ANA-positive participants showed more epitope
238 hits, independent of age (**Fig. S3B**). When combining data of all available epitopes, we found
239 significantly more hits in ANA-positive compared to ANA-negative participants, which was
240 most pronounced at younger age (**Fig. 5I**). Thus, human virome-wide serological profiling in
241 acute COVID-19 revealed antibodies cross-reactive to other coronaviruses, whereas ANA-
242 positive participants producing antibodies to more viral epitopes on a virome wide level.

243

244 **Association of autoantibodies with inflammatory signature during acute COVID-19**

245 Several studies have associated autoantibodies with severe COVID-19.^{11,15,17-19} Thus, we
246 sought to further characterize ANA-positive and ANA-negative COVID-19 patients during
247 acute disease by proteomics comprising 86 inflammatory markers, cytokine measurements,
248 flow cytometry, clinical history, and routine diagnostic analyses. The proportion of participants
249 with a known autoimmune disease was low in our cohort and indifferent in individuals with or
250 without ANA or ANCA (**Table 2**). We found a higher prevalence of comorbidities in
251 autoantibody-positive patients, including hypertension and heart disease, but no significant sex
252 difference (**Table 2**).

253 A multivariate analysis with 130 variables, including demographic parameters, routine
254 diagnostic measurements, and inflammation markers obtained by proteomics (**Table S5**),

255 allowed for a nearly complete separation of severe COVID-19 patients from healthy
256 individuals, with mild COVID-19 patients exhibiting intermediate characteristics (**Fig. 6A**).
257 Several markers contributing to severe COVID-19 were significantly higher ($p < 0.05$) in
258 ANA-positive than ANA-negative COVID-19 patients, revealing an inflammatory signature
259 associated with severe disease in ANA-positive individuals (**Fig. 6B**). Importantly, ANA-
260 positive COVID-19 patients were older and experienced longer hospitalization (**Fig. 6C**), and
261 many inflammation markers, including C-reactive protein (CRP) and interleukin (IL)-6, were
262 elevated compared to ANA-negative patients (**Fig. 6D**). Furthermore, ANA-positivity was
263 associated with T cell activation as suggested by higher soluble IL-2 receptor alpha (sIL-2R α)
264 serum concentrations and increased proportions of activated CD38⁺ HLA-DR⁺ CD4⁺ and CD8⁺
265 T cells (**Fig. 6E**). Similar trends toward an inflammatory signature were also observed in
266 ANCA-positive individuals during acute COVID-19, although these results were limited due
267 to lower prevalence of ANCA (**Fig. S4A and B**).

268 Finally, we assessed characteristics of ANA-positive and ANA-negative COVID-19 patients
269 at six months after acute disease to identify alterations in the absence of acute inflammation. A
270 multivariate analysis of 43 parameters, including patient characteristics and routine diagnostic
271 measurements, revealed differences comparing ANA-positive and ANA-negative individuals,
272 with several inflammation markers, including IL-6, tumor necrosis factor alpha (TNF- α), and
273 sIL-2R α , being significantly higher in ANA-positive participants (**Fig. 6F and G, Table S6**).
274 Interestingly, we also observed differences in Ig subclasses, with significantly higher IgG1 and
275 significantly lower IgM in ANA-positive individuals (**Fig. 6H**). Furthermore, marked changes
276 in B cell subsets were apparent, with higher frequencies of IgD⁺ CD27⁻ naïve B cells and lower
277 frequencies of IgD⁺ CD27⁺ non-switched and IgD⁻ CD27⁺ switched memory B cells in ANA-
278 positive individuals (**Fig. 6I**). Altogether, in autoantibody-positive COVID-19 patients, we
279 found an inflammatory signature during acute disease resembling alterations found in severe

280 disease and changes in inflammation markers, Ig subclasses, and B cells at six months after

281 recovery.

282

283 Discussion

284 Although autoantibodies targeting nuclear, cytoplasmic, and soluble autoantigens following
285 viral infections have been well described,^{28,29} their significance has remained ill-defined. In
286 this study, we used highly sensitive assays to detect ANA and ANCA, representing systemic
287 autoantibodies, in patients up to one year after infection with SARS-CoV-2. Firstly, we found
288 transient ANA and ANCA in a subgroup of participants during acute COVID-19. Autoantibody
289 production could result from activation of autoreactive B and T cells recognizing viral epitopes
290 by means of molecular mimicry.^{30,31} Alternatively, antigen-independent 'bystander' activation
291 of autoreactive B and T cells by cytokines and other inflammatory mediators could drive
292 autoantibody production.^{32,33} Particularly in severe COVID-19, which is associated with early
293 neutrophilia and pronounced neutrophil extracellular trap (NET) formation,^{34,35} NETs expose
294 shielded intracellular self-antigens,^{25,36,37} thus causing production of ANCA and ANA.
295 Interestingly, a high prevalence of IgA ANCA has been reported in acute COVID-19 patients
296 showing chilblain-like lesions.²¹ In our study, all ANCA-positive subjects tested negative for
297 anti-MPO and anti-PR3 antibodies, thus it remains elusive whether these ANCA have
298 pathogenic potential.

299 Secondly, we found distinct features in autoantibody-positive COVID-19 patients during acute
300 disease and recovery. Autoantibodies were associated with prolonged hospitalization and
301 inflammation markers during acute disease, supporting recent findings.^{11,15,17-19,38,39} Whereas
302 autoantibodies targeting type I interferons have been linked to severe COVID-19,^{10-12,16} severe
303 COVID-19 could decrease self-tolerance by tissue damage and inflammation, altogether
304 leading to generation of autoantibodies. However, confounding factors should be considered,
305 such as age and comorbidities, affecting prevalence of autoantibodies⁴⁰ and risk of severe
306 COVID-19¹. Following these considerations, we found changes in ANA-positive individuals
307 even six months after acute COVID-19, indicating ongoing low-grade inflammation.

308 Furthermore, we observed alterations of the B cell compartment, including increased naïve and
309 decreased memory B cells, previously associated with pre-symptomatic and early-stage
310 autoimmune diseases.⁴¹⁻⁴³ Differences in total Ig concentrations have been found in
311 autoimmune diseases⁴⁴ and patients suffering from post-acute COVID-19 syndrome (PACS)⁴⁵.
312 Thus, we have previously identified an Ig signature in PACS, including low total IgM, and
313 found clinical risk factors, including increased age and severe disease course.⁴⁵ Although a
314 direct link to autoantibody development in PACS has not been reported, a misdirected immune
315 response may underly both manifestations.

316 Thirdly, we observed higher S1-specific antibody titers in autoantibody-positive COVID-19
317 patients. Similarly, recent reports found increased anti-viral humoral responses in
318 autoantibody-positive individuals during acute COVID-19, although the interrelation remained
319 unclear.^{16,19,22} Interestingly, following COVID-19 mRNA vaccination in systemic lupus
320 erythematosus (SLE) patients, higher humoral responses positively correlated with anti-
321 dsDNA antibodies,³⁹ supporting our findings of increased S1-specific IgA production in ANA-
322 positive individuals following vaccination. These findings indicate an inherent capacity of
323 ANA-positive individuals to mount more robust antibody responses upon antigen challenge.

324 Human virome-wide serological profiling revealed production of cross-reactive antibodies to
325 other coronaviruses during acute COVID-19, particularly in severe disease, consistent with
326 broader humoral immune responses in severe COVID-19.²⁷ Whereas antibodies targeted
327 similar cross-reactive coronavirus epitopes in ANA-positive and ANA-negative COVID-19
328 patients, more antibodies targeted EBV antigen EBNA-2 in ANA-positive individuals. Higher
329 humoral responses against EBV have been described in ANA-positive individuals, irrespective
330 of autoimmune disease.^{46,47} Also, EBV has been associated with development of ANA and
331 SLE.⁴⁸ Furthermore, severe acute COVID-19 is characterized by extrafollicular B cell
332 activation,^{20,38,49} which is found in autoimmune disease and associated with activation of

333 autoreactive B cells. This increased response could allow for rapid formation of virus-specific
334 antibody-secreting cells,²⁰ potentially explaining why individuals with autoantibodies exhibit
335 higher humoral responses during acute COVID-19. Whether autoantibody-positive subjects
336 also show increased SARS-CoV-2-specific long-lived T cells responses⁵⁰ remains to be
337 investigated.

338 Limitations of this study include the use of highly sensitive IIF assays that yielded a high
339 prevalence of positive results in healthy subjects and COVID-19 patients. Most of the measured
340 ANA titers were at or just above the threshold level, which usually would be considered of
341 irrelevant clinical significance. Moreover, we did not assess the specificity of autoantibodies,
342 but recent studies have shown reactivity to a wide spectrum of autoantigens.^{11,16}

343 Altogether, our study shows autoantibodies in COVID-19 appear to be transient and correlate
344 with increased anti-viral humoral immune responses and a distinct immune signature. As
345 questions arise regarding long-term consequences of COVID-19, including the risk of immune
346 dysregulation and autoimmune disease, understanding the mechanisms involved in balancing
347 self-tolerance and protective immune responses become crucial to recognize and manage
348 patients at risk for developing autoimmune diseases.

349

350 **Methods**

351 **Human subjects and patient characteristics**

352 Following written informed consent, adult individuals were recruited for medical history and
353 blood sampling between April 2020 and May 2021. The study was approved by the Cantonal
354 Ethics Committee of Zurich (BASEC #2016-01440). The cohort comprised mild and severe
355 COVID-19 patients, healthy controls, and vaccinated individuals.

356 *COVID-19 patients (Table 1, Table S1)*: 175 patients with reverse transcriptase quantitative
357 polymerase chain reaction (RT-qPCR)-confirmed SARS-CoV-2 infection were included
358 during acute COVID-19 at four hospitals in the Canton of Zurich, Switzerland. COVID-19 was
359 classified for maximum disease severity according to the World Health Organization (WHO)
360 classification criteria into mild disease – including asymptomatic (n = 4), mild illness (n = 93)
361 and mild pneumonia (n = 12) – and severe disease – including severe pneumonia (n = 30) and
362 acute respiratory distress syndrome (n = 36)⁵¹. Follow-up visits for medical history and blood
363 collection were conducted approximately six months and one year after symptom onset.
364 Unreachable individuals or those declining further participation were lost to follow-up.

365 *Healthy controls (Table 1)*: 41 participants with negative history of SARS-CoV-2 infection
366 and serology were recruited. Five individuals developed COVID-19 after inclusion and were
367 subsequently allocated to the patient cohort.

368 *Vaccinated individuals (Table S2)*: 11 individuals with a negative history and serology for
369 SARS-CoV-2 infection were sampled once before vaccination, once after the first and twice
370 after the second mRNA vaccination with BNT162b2 (BioNTech-Pfizer).

371

372 **Autoantibody detection**

373 ANA were measured by IIF on HEp-2 cells (Euroimmun) with a cut-off dilution of 1:320.

374 ANCA were measured by IIF on neutrophils fixed by ethanol and formalin (Euroimmun) with

375 a cut-off dilution of 1:40. IIF imaging was performed using a diagnostic, computer-aided
376 microscopy system (Euroimmun). ANA patterns were classified according to the international
377 consensus on ANA patterns anti-cell (AC) nomenclature²³ by blinded trained personnel. For
378 paired analyses of ANA patterns, 129 pairs of IIF pictures at 1:320 dilution were blinded for
379 patient characteristics and sampling timepoint, and examined pairwise by the same observer.
380 Antibodies against myeloperoxidase and proteinase 3 were measured on PhadiaTM 250
381 (ThermoFisher Scientific) or on Bioflash[®] (Werfen) according to manufacturer's instructions.

382

383 **Immunoassays**

384 Immunoassays for Ig subsets, anti-SARS-CoV-2 spike S1-specific IgA and IgG, interleukin
385 (IL)-1 β , IL-2, IL-5, IL-6, IL-10, IL-12, interferon- γ (IFN- γ), sIL-2R α , and tumor necrosis
386 factor α (TNF- α), were performed in accredited laboratories at University Hospital Zurich.
387 Serum Ig subsets were quantified on an Optilite[®] turbidimeter (The Binding Site Group). S1-
388 specific IgA and IgG were measured by enzyme-linked immunosorbent assays (ELISA)
389 (Euroimmun), as established⁵². IL-1 β , IL-2, IL-6, IFN- γ and sIL-2R α were determined by
390 ELISA (R&D Systems) on Opsys ReaderTM (Dy nex). IL-5, IL-10 and IL-12 were measured by
391 cytometric bead assays (BD Biosciences) on a Navios cytometer (Beckman Coulter). TNF- α
392 was determined with a kit (R&D Systems) using MagPix[®] (ThermoFisher Scientific).

393

394 **Flow cytometry**

395 As established⁵³, blood samples were processed and analyzed in accredited laboratories at
396 University Hospital Zurich. Blood samples were lysed with VersaLyse, fixed with IOTest3
397 solution and stained with antibodies (Beckman Coulter; **Table S7**). Absolute cell counts were
398 determined using Flow Set Pro Fluorospheres calibration beads on Navios (Beckman Coulter).

399

400 **Serum proteomics**

401 Serum samples were analyzed by a proximity extension assay-based technology 92-plex
402 inflammation panel (Olink[®]), as established^{33,53,54}. Six parameters were excluded because less
403 than 50% of samples showed results above detection limit.

404

405 **Human virome-wide serological profiling**

406 As established,^{7,55} serum samples were inactivated, normalized for total IgG concentration, and
407 incubated as duplicates with a bacteriophage library displaying linear, 56 amino acid long viral
408 epitopes. IgG-phage complexes were captured with magnetic beads, lysed and quantified by
409 next-generation sequencing. Blank beads samples were used as negative controls. Reads were
410 mapped to the epitope library with Bowtie2, and counts were obtained using SAMtools. A
411 previously described binning strategy was used to identify positivity for epitopes,⁵⁶ with a
412 minimum z-score of 3.5 for both sample replicates compared to negative controls. Results for
413 a total of 112 different human viruses were included in the further analysis. (**Table S4**),
414 whereas eukaryotes, prokaryotes, non-human viruses and human viruses with no variance or a
415 maximal summed epitope hit count below three were excluded.

416

417 **Statistics**

418 Statistical analyses were performed using R (version 4.1.0). Unless otherwise specified,
419 between-group comparison was performed using two-tailed, non-parametric, unpaired testing
420 (Mann-Whitney U) for numeric variables and odds ratios with Fisher's exact test for categorical
421 variables, with p-values of <0.05 defined as significant. Missing values were omitted. Principal
422 component analyses (PCA) were performed using stats (4.2.0) and factoextra (1.0.7) with
423 scaled, centered variables, and loadings are shown as variable coordinates. Spearman's rank
424 correlation was used for associations of numeric variables. Pairwise protein alignment for 56-

425 amino acid (AA) long peptides with SARS-CoV-2 spike (Uniprot Entry P0DTC2) and
426 nucleoprotein (P0DTC9) was generated using Biostrings (2.60.2), with BLOSUM62
427 substitution matrix and gap opening and extension penalty of -11 and -1, respectively. Data
428 visualization was performed using ggplot2 (version 3.3.5), ggfortify (0.4.12), ggVennDiagram
429 (1.1.4), UpSetR (1.4.0), and corrplot (0.90). Horizontal lines in violin plots represent medians.
430 Regression lines represent simple linear regression models.

431

432 Word count: 3840

433

434 **Author contributions**

435 P.T. contributed to patient recruitment and data collection, analysis and interpretation. C.C.
436 contributed to patient recruitment, data collection and data interpretation. Y.Z., S.H., and S.A.
437 contributed to patient recruitment and data collection. C.P., Z.T., and P.B. contributed to data
438 collection. M.E.R. contributed to patient recruitment and clinical management. E.B., A.R.,
439 M.S.-H., L.C.H., and J.N. contributed to patient recruitment. E.P.-M. contributed to data
440 analysis. O.B. conceived the project and interpreted the data. P.T. and O.B. wrote the
441 manuscript. All authors edited and approved the final draft of the article.

442

443 **Conflict of interest statement**

444 The authors declare no conflict of interest in relation to this work.

445

446 References

- 447 1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
448 China. *N Engl J Med*. 2020;382(18):1708-1720.
- 449 2. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and
450 influenza pandemics. *Lancet Infect Dis*. 2020;20(9):e238-e244.
- 451 3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
452 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
453 Review. *JAMA*. 2020;324(8):782-793.
- 454 4. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. *Curr Opin*
455 *Rheumatol*. 2021;33(2):155-162.
- 456 5. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in
457 Patients with Covid-19. *N Engl J Med*. 2020;382(17):e38.
- 458 6. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome Associated with
459 SARS-CoV-2. *N Engl J Med*. 2020;382(26):2574-2576.
- 460 7. Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem
461 Inflammatory Syndrome in Children with COVID-19. *Cell*. 2020;183(4):968-
462 981.e967.
- 463 8. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients
464 hospitalized with COVID-19. *Sci Transl Med*. 2020;12(570).
- 465 9. Hsu TY, D'Silva KM, Patel NJ, Fu X, Wallace ZS, Sparks JA. Incident systemic
466 rheumatic disease following COVID-19. *Lancet Rheumatol*. 2021;3(6):e402-e404.
- 467 10. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients
468 with life-threatening COVID-19. *Science*. 2020;370(6515).
- 469 11. Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with
470 COVID-19. *Nature*. 2021;595(7866):283-288.
- 471 12. Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are
472 present in. *Sci Immunol*. 2021;6(62).
- 473 13. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander
474 activation, or viral persistence: infections and autoimmune disease. *Clin Microbiol Rev*.
475 2006;19(1):80-94.
- 476 14. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to
477 systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. *Ann*
478 *Rheum Dis*. 2020;79(12):1661-1663.
- 479 15. Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of
480 autoimmune response. *Clin Transl Sci*. 2021;14(3):898-907.
- 481 16. Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized
482 patients with COVID-19. *Nat Commun*. 2021;12(1):5417.
- 483 17. Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and Immunological
484 Dysregulation: Can Autoantibodies be Useful? *Clin Transl Sci*. 2021;14(2):502-508.
- 485 18. Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-
486 19. *Clin Transl Sci*. 2021.
- 487 19. Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of
488 autoantibody responses in acute coronavirus disease 2019 (COVID-19). *J Transl*
489 *Autoimmun*. 2020;3:100073.
- 490 20. Woodruff MC, Ramonell RP, Saini AS, et al. Relaxed peripheral tolerance drives broad.
491 *medRxiv*. 2021.
- 492 21. Frumholtz L, Bouaziz JD, Battistella M, et al. Type I interferon response and vascular
493 alteration in chilblain-like lesions during the COVID-19 outbreak. *Br J Dermatol*. 2021.

- 494 22. Emmenegger M, Kumar SS, Emmenegger V, et al. Anti-prothrombin autoantibodies
495 enriched after infection with SARS-CoV-2 and influenced by strength of antibody
496 response against SARS-CoV-2 proteins. *PLoS Pathog.* 2021;17(12):e1010118.
- 497 23. Chan EK, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus
498 on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-
499 2015. *Front Immunol.* 2015;6:412.
- 500 24. Suwanchote S, Rachayon M, Rodsaward P, et al. Anti-neutrophil cytoplasmic
501 antibodies and their clinical significance. *Clin Rheumatol.* 2018;37(4):875-884.
- 502 25. Nakazawa D, Kumar S, Desai J, Anders HJ. Neutrophil extracellular traps in tissue
503 pathology. *Histol Histopathol.* 2017;32(3):203-213.
- 504 26. Xu GJ, Kula T, Xu Q, et al. Viral immunology. Comprehensive serological profiling of
505 human populations using a synthetic human virome. *Science.* 2015;348(6239):aaa0698.
- 506 27. Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID-19 patients
507 reveals cross-reactivity and correlates of severity. *Science.* 2020;370(6520).
- 508 28. Hansen KE, Arnason J, Bridges AJ. Autoantibodies and common viral illnesses. *Semin*
509 *Arthritis Rheum.* 1998;27(5):263-271.
- 510 29. Spohn G, Arenas-Ramirez N, Bouchaud G, Boyman O. Endogenous polyclonal anti-
511 IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation. *J*
512 *Allergy Clin Immunol.* 2017;139(6):1957-1965.e1953.
- 513 30. Moody R, Wilson KL, Boer JC, et al. Predicted B Cell Epitopes Highlight the Potential
514 for COVID-19 to Drive Self-Reactive Immunity. *Frontiers in Bioinformatics.*
515 2021;1(31).
- 516 31. Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, JI Macario A,
517 Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19.
518 *Autoimmun Rev.* 2020;19(8):102591.
- 519 32. Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med.* 2020;383(23):2255-2273.
- 520 33. Chevrier S, Zurbuchen Y, Cervia C, et al. A distinct innate immune signature marks
521 progression from mild to severe COVID-19. *Cell Rep Med.* 2021;2(1):100166.
- 522 34. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. *JCI*
523 *Insight.* 2020;5(11).
- 524 35. Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. *Front*
525 *Immunol.* 2021;12:652470.
- 526 36. van der Linden M, van den Hoogen LL, Westerlaken GHA, et al. Neutrophil
527 extracellular trap release is associated with antinuclear antibodies in systemic lupus
528 erythematosus and anti-phospholipid syndrome. *Rheumatology (Oxford).*
529 2018;57(7):1228-1234.
- 530 37. Egholm C, Heeb LEM, Impellizzeri D, Boyman O. The Regulatory Effects of
531 Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses. *Front*
532 *Immunol.* 2019;10:2507.
- 533 38. Woodruff MC, Ramonell RP, Nguyen DC, et al. Extrafollicular B cell responses
534 correlate with neutralizing antibodies and morbidity in COVID-19. *Nat Immunol.*
535 2020;21(12):1506-1516.
- 536 39. Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of Immune Response and
537 Disease Status in SLE Patients Following SARS-CoV-2 Vaccination. *Arthritis*
538 *Rheumatol.* 2021.
- 539 40. Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence of Antinuclear
540 Antibodies in the United States. *Arthritis Rheumatol.* 2020;72(6):1026-1035.
- 541 41. Baglaenko Y, Chang NH, Johnson SR, et al. The presence of anti-nuclear antibodies
542 alone is associated with changes in B cell activation and T follicular helper cells similar

- 543 to those in systemic autoimmune rheumatic disease. *Arthritis Res Ther.*
544 2018;20(1):264.
- 545 42. Zhu L, Yin Z, Ju B, et al. Altered frequencies of memory B cells in new-onset systemic
546 lupus erythematosus patients. *Clin Rheumatol.* 2018;37(1):205-212.
- 547 43. Slight-Webb S, Lu R, Ritterhouse LL, et al. Autoantibody-Positive Healthy Individuals
548 Display Unique Immune Profiles That May Regulate Autoimmunity. *Arthritis*
549 *Rheumatol.* 2016;68(10):2492-2502.
- 550 44. Zhang H, Li P, Wu D, et al. Serum IgG subclasses in autoimmune diseases. *Medicine*
551 *(Baltimore).* 2015;94(2):e387.
- 552 45. Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of
553 post-acute COVID-19 syndrome. *Nat Commun.* 2022;13(1):446.
- 554 46. Slight-Webb S, Smith M, Bylinska A, et al. Autoantibody-positive healthy individuals
555 with lower lupus risk display a unique immune endotype. *J Allergy Clin Immunol.*
556 2020;146(6):1419-1433.
- 557 47. Jog NR, Young KA, Munroe ME, et al. Association of Epstein-Barr virus serological
558 reactivation with transitioning to systemic lupus erythematosus in at-risk individuals.
559 *Ann Rheum Dis.* 2019;78(9):1235-1241.
- 560 48. Cuomo L, Cirone M, Di Gregorio AO, et al. Elevated antinuclear antibodies and altered
561 anti-Epstein-Barr virus immune responses. *Virus Res.* 2015;195:95-99.
- 562 49. Kaneko N, Kuo HH, Boucau J, et al. Loss of Bcl-6-Expressing T Follicular Helper Cells
563 and Germinal Centers in COVID-19. *Cell.* 2020;183(1):143-157.e113.
- 564 50. Adamo S, Michler J, Zurbuchen Y, et al. Signature of long-lived memory CD8. *Nature.*
565 2021.
- 566 51. WHO. COVID-19 Clinical management: living guidance. World Health Organization
567 (2021), doi: www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. In.
- 568 52. Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses
569 specific to SARS-CoV-2 during mild versus severe COVID-19. *J Allergy Clin*
570 *Immunol.* 2021;147(2):545-557.e549.
- 571 53. Adamo S, Chevrier S, Cervia C, et al. Profound dysregulation of T cell homeostasis
572 and function in patients with severe COVID-19. *Allergy.* 2021;76(9):2866-2881.
- 573 54. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-
574 based proximity extension assays provide sensitive and specific detection of low-
575 abundant proteins in human blood. *Nucleic Acids Res.* 2011;39(15):e102.
- 576 55. Pou C, Nkulikiyimfura D, Henckel E, et al. The repertoire of maternal anti-viral
577 antibodies in human newborns. *Nat Med.* 2019;25(4):591-596.
- 578 56. Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting
579 antibodies that offer protection from other pathogens. *Science.* 2019;366(6465):599-
580 606.
- 581

582 **Table 1. COVID-19 study cohort characteristics.**

		Healthy controls	COVID-19 Acute disease		COVID-19 6-month follow-up	
	Disease severity n (%)	41	Mild	Severe	Mild	Severe
Patient characteristics	Age	32 (28–52)	34 (28–52)	68 (57–78)	36 (29–53)	64 (58–74)
	Days after symptom onset		10 (7–16)	14 (9–27)	194 (185–205)	211 (194–224)
	Sex (female)	24 (58.5%)	54 (49.5%)	27 (40.9%)	40 (51.3%)	14 (35.9%)
	Vaccinated	0	0	0	9 (11.7%)	3 (7.7%)
	Hospitalized	–	20 (18.3%)	66 (100%)	12 (15.6%)	39 (100%)
Laboratory parameters	Lymphocyte count (G/l)	1.80 (1.48–2.33)	1.81 (1.18–2.23) ns	0.76 (0.56–1.10)****	1.96 (1.67–2.37) ns	1.77 (1.48–2.34) ns
	CRP (mg/l)	0.6 (0.4–1.6)	1.3 (0.6–5.3)**	59.2 (32.2–119.0)****	0.6 (0.6–1.3) ns	1.7 (2.2–5.1)**
	TNF- α (ng/l)	8.1 (6.4–10.0)	9.8 (7.6–12)**	16.4 (13.0–20.6)****	9 (6.8–10.9) ns	11.8 (9.3–15.0)****
	IL-6 (ng/l)	0.5 (0–1.1)	1.3 (0.1–4.9)***	19.5 (7.4–57.0)****	0.9 (0–2.1)*	1.6 (0.3–5.3)**
	S1-specific IgA (OD ratio)	0.33 (0.25–0.46)	1.77 (0.73–4.81)****	7.24 (2.52–10.2)****	2.52 (1.54–4.96)****	5.09 (3.12–7.75)****
	S1-specific IgG (OD ratio)	0.20 (0.17–0.25)	0.61 (0.27–2.19)****	5.12 (0.32–9.33)****	2.67 (1.29–5.69)****	6.91 (5.18–8.49)****
Comorbidities	Hypertension (n)	5 (12.2%)	12 (11.0%) ns	38 (57.8%)***	6 (7.8%) ns	21 (53.8%)**
	Diabetes (n)	2 (4.9%)	6 (5.5%) ns	19 (28.8%)*	4 (5.2%) ns	12 (30.7%)**
	Heart disease (n)	1 (2.4%)	6 (5.5%) ns	24 (36.6%)***	2 (2.6%) ns	15 (38.5%)***
	Lung disease (n)	5 (12.2%)	10 (9.2%) ns	12 (18.8%)*	5 (6.5%) ns	11 (28.2%) ns
	Malignancy (n)	1 (2.4%)	3 (2.8%) ns	8 (12.1%)*	3 (3.9%) ns	5 (12.8%) ns
	Kidney disease (n)	0 (0%)	8 (7.3%) ns	17 (25.8%)***	3 (3.9%) ns	10 (25.6%)**
	Autoimmune disease (n)	3 (7.3%)	6 (5.5%) ns	7 (10.6%) ns	6 (7.8%) ns	6 (15.4%) ns

583 Medians and interquartile ranges (in parentheses) are specified for continuous variables, with p-values obtained by Mann-Whitney U test, compared
584 to healthy individuals. Numbers of individuals (n) and percentages of corresponding subgroup (in parentheses) are shown for categorical variables,
585 with p-values calculated by Fisher’s exact test, in comparison to healthy individuals. ns, non-significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001;
586 ****, p < 0.0001. OD, optical density.
587

588 **Table 2. Characteristics of ANA- or ANCA-positive and -negative COVID-19 patients at acute disease or six months after infection.**

		COVID-19 Acute disease			COVID-19 6-month follow-up			
		ANA-negative	ANA-positive	p-value	ANA-negative	ANA-positive	p-value	
ANA								
Patient characteristics	n (%)	91 (52.0%)	84 (48.0%)	–	61 (52.6%)	55 (47.4%)	–	
	Age	38 (30–58)	60.5 (38–73)	***	33(29-47)	61 (45–69)	****	
	Days after symptom onset	11 (7–16)	12 (7–19)	ns	195 (186–206)	204 (183–218)	ns	
	Sex (female)	43 (47.3%)	38 (45.2%)	OR 0.92, ns	29 (47.5%)	25 (45.5%)	OR 0.95, ns	
	Comorbidities	Hypertension	18 (19.7%)	32 (38.1%)	OR 2.48, *	8 (12.1%)	19 (34.5%)	OR 3.39, **
		Diabetes mellitus	12 (13.2%)	13 (15.5%)	OR 1.20, ns	6 (9.8%)	10 (18.2%)	OR 1.99, ns
		Heart disease	9 (9.9%)	21 (25.0%)	OR 3.02, **	1 (1.6%)	16 (29.1%)	OR 23.68, ***
		Lung disease	15 (16.5%)	7 (8.3%)	OR 0.46, ns	9 (14.8%)	7 (12.7%)	OR 0.87, ns
Kidney disease		11 (12.1%)	14 (16.7%)	OR 1.45, ns	2 (3.3%)	11 (20.0%)	OR 7.14, **	
Malignancy		4 (4.4%)	8 (9.5%)	OR 2.28, ns	4 (6.6%)	5 (9.1%)	OR 1.40, ns	
Autoimmune disease		8 (8.7%)	5 (5.9%)	OR 0.66, ns	5 (8.2%)	7 (12.7%)	OR 1.62, ns	
ANCA								
Patient characteristics	n (%)	158 (90.3%)	17 (9.7%)	–	113 (97.4%)	3 (2.6%)	–	
	Age	44 (32–65)	71 (57–80)	***	43 (31–64)	69 (64–70)	–	
	Days after symptom onset	11 (7–16)	11 (9–19)	ns	199 (187–216)	182 (164–212)	–	
	Sex (female)	74 (46.8%)	7 (41.2%)	OR 0.79, ns	52 (46.0%)	1 (33.3%)	–	
	Comorbidities	Hypertension	41 (25.9%)	9 (52.4%)	OR 3.19, *	27 (23.9%)	0 (0%)	–
		Diabetes mellitus	21 (13.2%)	4 (23.5%)	OR 2.00, ns	15 (13.3%)	1 (33.3%)	–
		Heart disease	24 (15.2%)	6 (35.2%)	OR 3.02, ns	16 (14.2%)	1 (33.3%)	–
		Lung disease	21 (13.3%)	1 (5.9%)	OR 0.41, ns	15 (13.3%)	1 (33.3%)	–
Kidney disease		22 (13.9%)	3 (17.6%)	OR 1.32, ns	12 (10.6%)	1 (33.3%)	–	
Malignancy		10 (5.9%)	2 (11.8%)	OR 1.96, ns	8 (7.1%)	1 (33.3%)	–	
Autoimmune disease		12 (7.6%)	1 (5.9%)	OR 0.76, ns	12 (10.6%)	1 (33.3%)	–	

589 For continuous variables, medians and interquartile ranges (in parentheses) are specified, with p-values obtained by Mann-Whitney U test
 590 comparing individuals with and without autoantibodies. For categorical variables, numbers of individuals (n) and percentages of the
 591 corresponding subgroup (in parentheses) and odds ratios (OR) with p-values indicating significance in Fisher’s exact test are shown. ns, non-
 592 significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

593 **Figure legends**

594 **Figure 1. Prevalence of autoantibodies in healthy controls and COVID-19 patients during**
595 **acute disease and follow-up.** (A) Study overview. (B–I) Prevalence of ANA titers (B-E) and
596 ANCA (F-I) in healthy controls (n = 41) and COVID-19 patients during acute disease (n =
597 175), six months (n = 116) and one year (n = 92) after symptom onset. (J–M) Venn diagrams
598 depicting co-occurrence of nuclear ANA, cytoplasmic ANA and ANCA in healthy individuals
599 (J; n = 17), acute COVID-19 patients (K; n = 89) and COVID-19 patients six months (L; n =
600 56) or one year (M; n = 42) after SARS-CoV-2 infection that presented with at least one type
601 of autoantibody. P-values indicate comparison of ANA (B-E) and ANCA (F-I) prevalence
602 between mild and severe COVID-19 patients using Fisher’s exact test.

603 **Figure 2. IIF pattern of autoantibodies in acute and recovered COVID-19. (A–D)**
604 Intersection plots showing counts of the four most prevalent ANA patterns (horizontal bars)
605 and counts of pattern combinations (vertical bars) as indicated by the dot matrix, for healthy
606 controls (A), and COVID-19 patients during acute disease (B), six months (C) and one year
607 after symptom onset (D). (E–G) Example IIF pictures showing the most common nuclear,
608 including fine-granular (E) and nucleolar (F), and cytoplasmic, including speckled (G), ANA
609 patterns observed in the study cohort. All images were recorded at a dilution of 1:320. y/o,
610 years old. (H) IIF ANCA patterns observed in ANCA-positive COVID-19 patients during acute
611 disease (n = 17) and six months after recovery (n = 3). (I) Anti-MPO and anti-PR3 antibodies
612 during acute COVID-19 (n = 175) in ANCA-positive and ANCA-negative individuals. Dashed
613 lines indicate diagnostic cut-off values.

614 **Figure 3. Paired longitudinal comparison indicates transient induction of autoantibodies**
615 **in acute COVID-19. (A–B)** Temporal trajectory of ANA titers in mild (A, n = 85) and severe
616 (B, n = 44) COVID-19 patients, showing the first available follow-up sample, i.e. at six months
617 (n = 116) or one year (n = 13) after symptom onset. Colors indicate development of ANA status
618 from acute disease to follow-up. (C) Results from blinded, paired IIF picture analysis (n = 129).
619 Patterns that were uniquely observed at one timepoint are colored. (D) Exemplary IIF pictures
620 of three patients exhibiting transient ANA patterns during acute COVID-19, with a transient
621 nucleolar (left), cytoplasmic (middle), or mitotic (right) pattern. All pictures were recorded at
622 a dilution of 1:320. y/o, years old. (E–F) Temporal trajectory of ANCA titers in mild (E, n =
623 85) and severe (F, n = 44) COVID-19 patients. Colors indicate development of ANCA status
624 from acute disease to follow-up.


625 **Figure 4. Presence of autoantibodies is associated with an increased virus-specific**
626 **humoral response after SARS-CoV-2 infection and vaccination. (A–B)** S1-specific IgA and
627 IgG in ANA-positive and ANA-negative COVID-19 patients during acute disease (n = 175)
628 and six months after recovery (n = 104). (B) P-values indicate significance of the correlation
629 of ANA positivity as an independent parameter in a multiple linear regression model
630 accounting for age, disease severity and sampling timepoint (**Table S3**). (C) S1-specific IgA
631 and IgG in ANCA-positive and ANCA-negative COVID-19 patients during acute disease (n =
632 175). (D) ANA prevalence and titers in previously unexposed individuals (n = 11) before and
633 after vaccination with BNT162b2 at indicated timepoints. The p-value was calculated using
634 Chi-squared test of independence. (E) S1-specific IgA and IgG before and after COVID19
635 vaccination (n = 11). Red vertical lines indicate the timepoints of first and second vaccination
636 with BNT162b2. (F) S1-specific IgA and IgG in ANA-positive and ANA-negative participants
637 following COVID-19 vaccination with BNT162b2, combining data from 10-13d after the first
638 (n = 11) and 1-3d after the second (n = 10) vaccination.

639 **Figure 5. Comprehensive serological profiling (VirScan) in ANA-positive and ANA-**
640 **negative individuals during acute COVID-19. (A)** Principal component analysis (PCA) of
641 112 viral species, including data of 18 healthy individuals and 96 acute COVID-19 patients,
642 grouped by timepoint of sample collection after symptom onset. Each dot represents an
643 individual participant. **(B)** Loadings of PCA depicted in (A), with each viral species shown as
644 individual dots (**Table S4**). Colors indicate participant groups with higher mean epitope hits
645 per species. Viral species with significant difference ($p < 0.005$) between COVID-19 patients
646 and healthy controls are shown as large colored dots. Black crosses indicate insignificant
647 differences of coronaviruses ($p > 0.005$). **(C)** Temporal association of summed epitope hits of
648 six coronaviruses after symptom onset, shown for acute COVID-19 patients ($n = 97$) and
649 healthy controls ($n = 18$). Horizontal green bars represent means of healthy controls. **(D)**
650 Percentage of healthy controls and COVID-19 patients with positive results for epitopes of six
651 coronavirus species. Significantly enriched epitopes ($p < 0.05$) of spike and nucleocapsid are
652 indicated accordingly. **(E–F)** Summed hits for cross-reactive epitopes, comparing healthy
653 controls and patients with mild and severe COVID-19 (E) or COVID-19 patients with or
654 without ANA (F). **(G)** Percentage of ANA-positive and ANA-negative COVID-19 patients
655 with positive results for cross-reactive and non-cross-reactive epitopes of six coronavirus
656 species. Dashed lines mark significance threshold at $p < 0.05$. **(H)** Percentage of ANA-positive
657 and ANA-negative study participants ($n = 115$) with positive results, shown for all available
658 epitopes. Significantly enriched epitopes ($p < 0.005$) are colored. EBV, Epstein-Barr virus;
659 HSV-2, herpes simplex virus 2; VZV, varizella-zoster virus; other, other viruses comprising
660 Aichivirus A and Mammastrovirus 1. **(I)** Summed epitope hits per individual including all
661 available epitopes, comparing ANA-negative and ANA-positive participants (top; $n = 115$),
662 and as a function of age (bottom).


663 **Figure 6. ANA-positive COVID-19 patients exhibit a pro-inflammatory signature. (A)**
664 PCA accounting for 130 parameters (**Table S5**) including data of healthy controls (n = 28) and
665 acute COVID-19 patients (n = 146). Participants with missing values were excluded from this
666 analysis. 95% confidence ellipses (t-distributed) are shown for healthy controls and severe
667 COVID-19 patients. **(B)** Loadings (variable coordinates) of the PCA depicted in (A), with each
668 parameter shown as an individual dot. Colors indicate the group of COVID-19 patients with
669 higher mean for each parameter, and parameters with significant differences ($p < 0.05$) are
670 represented as large dots and selected parameters are annotated (**Table S5**). **(C–E)** Comparison
671 of ANA-negative and -positive individuals among healthy controls or acute COVID-19
672 patients. **(C)** Patient characteristics, including duration of hospitalization (n = 174) and age (n
673 = 216). **(D)** Inflammation markers, including CRP (n = 209) and IL-6 (n = 215). **(E)** T cell
674 activation, including sIL-2R α (n = 215), and CD38⁺HLA-DR⁺ CD4⁺ (n = 210) and CD8⁺ (n =
675 209) T cells. **(F–G)** PCA **(F)** and loadings **(G)** accounting for 43 parameters (**Table S6**)
676 including data of COVID-19 patients six months after recovery (n = 107). Participants with
677 missing values were excluded from this analysis. **(H–I)** Comparison of ANA-negative and
678 ANA-positive COVID-19 patients six months after recovery. **(H)** Concentration of total Ig
679 subclasses in serum (n = 116). **(I)** Frequency of B cell subsets, including IgD⁺CD27⁻ naïve,
680 IgD⁺CD27⁺ non-switched memory and IgD⁻CD27⁺ switched memory B cells (n = 114).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).


A




B Healthy controls




C Acute COVID-19




D 6-month follow-up




E 1-year follow-up




F Healthy controls




G Acute COVID-19




H 6-month follow-up




I 1-year follow-up




J Healthy controls



K Acute COVID-19



L 6-month follow-up



M 1-year follow-up




Figure 1_Taescher et al.




Figure 2_Taeschler et al.




Figure 3_Taeschler et al.




Figure 4_Taeschler et al.




Figure 5_Taeschler et al.




Figure 6_Taescher et al.